

## Current information disclosure

Curative Biotechnology, Inc. announced today that Dimiter S. Dimitrov, PhD of the Department of Medicine at the University of Pittsburgh has joined the Curative Biotech Scientific and Clinical Advisory Board.

Dr. Dimitrov earned his PhD at the University of Sofia, Sofia, Bulgaria, and subsequently joined the National Cancer Institute (NCI) of the National Institutes of Health (NIH), USA, in 1990. There he was tenured as Senior Investigator and appointed at the Senior Biomedical Research Service. He left for the University of Pittsburgh in 2017 to start their Center for Antibody Therapeutics, where he serves as director. He was recently named one of 10 "Science Superheroes" by MediFind.

Dr. Dimitrov's major long-term goal is the development of clinically useful therapeutics and vaccines based on human monoclonal antibodies in different formats including engineered antibody domains, chimeric antigen receptors, bispecific antibodies and antibody drug conjugates. He has authored or coauthored more than 370 articles, several books, and is the inventor or coinventor of more than 100 inventions, patent applications or patents.

Dr. Dimitrov is the lead inventor on the Antibody Drug Conjugate patents exclusively licensed to Curative Biotech from the National Cancer Institute to treat glioblastoma and has joined the company's Scientific and Clinical Advisory Board to help guide the development of his invention into the clinic.